Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Larimar Therapeutics, Inc. (LRMR) had Free Cash Flow of $-26.59M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-29.28M |
|
-- |
|
-- |
|
$31.19M |
|
$-31.19M |
|
$1.91M |
|
$-29.28M |
|
$-29.28M |
|
$-29.28M |
|
$-29.28M |
|
$-29.28M |
|
$-29.28M |
|
$-31.19M |
|
$-31.86M |
|
63.96M |
|
63.96M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$165.49M |
|
$0.85M |
|
$4.69M |
|
$170.18M |
|
$22.13M |
|
-- |
|
$3.77M |
|
$25.90M |
|
$144.27M |
|
$144.27M |
|
$144.27M |
|
64.03M |
|
| Cash Flow Statement Financials | |
$-26.54M |
|
$14.45M |
|
-- |
|
$33.82M |
|
$21.73M |
|
$-12.09M |
|
$1.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
$-26.59M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.30% |
|
-20.30% |
|
-17.21% |
|
-20.30% |
|
$2.25 |
|
$-0.42 |
|
$-0.41 |
|